Review spotlights fisetin’s reproductive potential in mammals: full analysis
Version 2
A May 2026 review in Veterinary Sciences is putting fisetin on the reproductive-health radar for veterinary and animal science audiences. In “Role of Fisetin in the Mammalian Reproductive System,” authors Yuehua Chen, Xiaogang Huang, and Zhihong Zhao synthesize evidence that this naturally occurring flavonoid may help protect reproductive tissues through antioxidant, anti-inflammatory, anti-apoptotic, metabolic, and senescence-related pathways. At the same time, the paper is clear that the field is still early, with most data coming from laboratory and rodent models rather than clinical veterinary use. (mdpi.com)
That timing fits a broader trend. Fisetin has attracted growing attention in aging and natural-product research because of its reported senolytic and cytoprotective effects, and those mechanisms are now being explored in reproductive biology as well. A separate 2026 review focused on women’s reproductive health described the evidence base as promising but still largely experimental, while a 2024 veterinary longevity review noted there are no published pharmacokinetic studies in dogs or cats and no established FDA-approved veterinary indications for fisetin. (pubmed.ncbi.nlm.nih.gov)
The new Veterinary Sciences article centers on both female and male reproductive systems, highlighting potential effects on gonadal function, endocrine regulation, and the reproductive microenvironment. Supporting literature cited in search results includes a mouse study in which fisetin supplementation improved estrous cyclicity, estradiol levels, embryo numbers, follicular health, and ovarian oxidative-stress markers, with AMPK/mTOR signaling and mitophagy implicated in the response. Other recent preclinical work has suggested possible benefit in disease models such as polycystic ovary syndrome and testicular injury. (mdpi.com)
On the male side, one 2025 rat study from a veterinary theriogenology group reported that fisetin improved sperm motility and concentration and reduced oxidative stress after testicular torsion-detorsion injury, with the strongest effects seen when fisetin was combined with quercetin. That study also found shifts in apoptosis- and survival-related markers, including lower p53, Bax, and caspase-3 expression and higher AKT, PI3K, and Bcl-2 activity in treated groups. Those findings help explain why fisetin is drawing interest as a reproductive-support compound, even if the evidence remains far from clinical confirmation. (pubmed.ncbi.nlm.nih.gov)
Expert and industry commentary remains cautious. The 2026 Nutrients review from Johns Hopkins researchers concluded that fisetin may support ovarian function and hormonal balance and may influence fibrosis, metabolism, and cell growth across several reproductive conditions, but it also emphasized major gaps in mechanistic understanding and the need for clinical research. In veterinary medicine, the most relevant outside perspective appears to be from the 2024 longevity review, which described fisetin as promising for healthspan-related applications but underscored the lack of species-specific pharmacokinetic data and the possibility of adverse effects or drug interactions, including bleeding risk with blood thinners. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is a signal about research direction rather than a near-term therapeutic shift. Reproduction work in companion animals, livestock, and laboratory species increasingly overlaps with oxidative stress, inflammation, mitochondrial health, and aging biology, so fisetin is a plausible molecule of interest. But the distance between mechanistic promise and clinical utility is still wide. Dose, formulation, absorption, safety, species differences, residue considerations in food animals, and real-world reproductive outcomes all remain unresolved. Until those questions are answered, fisetin belongs in the “watch closely” category, not the routine toolkit. (mdpi.com)
What to watch: The next meaningful developments will likely be pharmacokinetic studies in target species, formulation work to improve bioavailability, and controlled trials that test whether fisetin can reliably improve fertility, gonadal resilience, or reproductive recovery in clinically relevant veterinary settings. If those data emerge, fisetin could move from an interesting nutraceutical candidate to a more serious reproductive-health research platform. (mdpi.com)